AML-BFM 2004

Author: Prof. Dr. med. Ursula Creutzig, erstellt 2003/07/24, Last modification: 2012/06/28

AML-BFM 2004 Acute myeloid leukaemia
Disease Acute myeloid leukaemia
Type Multicenter therapy optimising trial for the treatment of Acute myeloid leukeamia
Problem / Objectives

The AML-BFM 2004 trial is an multicenter dose-optimization trial for the treatment of acute myeloid leukeamias in children and adolescents. Patients are treatetd with a combination of intensive chemotherapy in combination with a radiation of the central nervous system (stopped with the amendment of April 2010) and /or haematopoietic stem cell transplantation.
The patients are stratified in a standard-group (SR) and a high risk-group (HR).

Therapy / Study arms

All randomizations are closed in April 2010. The trial is prolonged untill March 2011.
In the SR-Arm all patients receive liposomal daunorubicin. In the HR-Arm all patients receive 2-CDA as intensification during the consolidation course.
The prophylactic radiation of the central nervous system is stopped. The Investigator recommends the implementation of Triple-intrathecal injections.

Inclusion Criteria
  • Age from 0 to 18 years
  • De novo AML, incl. children with Down’s syndrome, primary myelosarcomas or acute mixed lineage leukeamia / biphenotypic leukeamia (predominantly myeloid)
  • Admission to one of the member hospitals in Germany participating in the study AML-BFM 2004
Exclusion Criteria
  • Children with pre-existing syndromes (except Down’s syndrome)
  • AML as secondary malignancy
  • Accompanying diseases which do not allow therapy according to the protocol
  • Pre-treatment for more than 14 days with another intensive induction therapy
Recruitment ca. 550
Status 01.03.2004-30.03.2011. Next trial is in planning stage.
Entry Study Register NCT00111345
Principal Investigator Prof. Dr. med. Dirk Reinhardt, Prof. Dr. Ursula Creutzig
E-Mail AML-BFM@MH-Hannover.DE
Contact UNICODEDECODEERROR: 'ascii' codec can't decode byte 0xe4 in position 9: ordinal not in range(128)

Prof. Dr. med. Ursula Creutzig


UNICODEDECODEERROR: 'ascii' codec can't decode byte 0xfc in position 11: ordinal not in range(128)
Weitere Informationen Creutzig U, Buchner T, Sauerland MC, Zimmermann M, Reinhardt D, Dohner H, Schlenk RF. Significance of age in acute myeloid leukemia patients younger than 30 years: a commom analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer 112: 562-71, 2008

Creutzig U. Treatment of acute myeloid leukemia in children. In: Pui CH, editor. Treatment of Acute Leukemias, New Directions for Clinical Research (St. Jude Children's Research Hospital, Memphis,TN). Totowa, NJ: Human Press Inc, 2003: 237-254

Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22: 4384-4393

Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, Jürgens H, Kabisch H, Reiter A, Riehm H, Gadner H, Schellong G. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia: 2005, 19: 2030-2042
Sponsoring Die AML-BFM 2004 trial is financially supported by the Deutsche Krebshife e.V.